k¶¹Ç®°ü

English

¹ú²ú¿¹XaÖÊÁ¿ÈôºÎ£¿¶àÖÐÐÄÁÙ´²×êÑÐÀ´Í¨ÖªÄ㣡

°ä²¼ÓÚ£º2023-09-20

ÎÄÕÂÆðÔ´£º[ÖÐÎÄ]k¶¹Ç®°üÉúÎï



ý½é


Ŀǰ£¬¾²ÂöѪ˨˨ÈûÐÔ¼²² ¡£¨venous thromboembolism, VTE£©ºÍ¶¯ÂöѪ˨˨ÈûÐÔ¼²²¡³ÉΪµ¼ÖÂÈ«ÇòÈ˶¡éæÃüµÄµÚһλԭÒò ¡£´óÎÞÊý¾²ÂöѪ˨ÓÉÓÚûÓÐÖ¢×´Ò×±»Â©Õï¡¢ÎóÕµ«VTEÊÇÄܹ»Ô¤·ÀµÄ£¬¿¹Äý¾ÍÊÇÔ¤·ÀºÍÒ½ÖεĻù´¡ ¡£µ«ÊÇÈôºÎÔ¤·À¿¹ÄýÒ½Öε¼ÖµijöѪÐÔ·çÏÕ£¬¡¶ÖйúѪ˨ÐÔ·ÀÖÎÖ¸ÄÏ¡·£¨2018£©¶ÔÓÚ·ÖÆç¿¹ÄýÒ©Îï¸ø³öÁËÓйصļà²âÖ¸±ê ¡£


  • ÈôÀûÓÃUFHÒ½ÖΣ¬ÍƼö³ÖÐø¾²Âö¸øÒ©²¢Æ¾¾Ý»î»¯²¿ÃÅÄýѪøԭ¹¦·ò£¨APTT£©¼à²âÁ˾ֵ÷½Ú¼ÁÁ¿£¬Ö±ÖÁAPTTµ¢¸éÖÁ¿¹ÄýǰµÄ1.5~2.5±¶£¬»ò´ïµ½Ï൱ÓÚѪ½¬UFHˮƽ0.3~0.7 U/ml ʱµÄ¿¹ XaÒò×Ó£¨FXa£©»îÐÔˮƽ¡¾1C¡¿ ¡£

  • ÖðÈÕÐè´ó¼ÁÁ¿UFHÒ½ÖζøAPTT²»´ï±êʱ£¬ÍƼöͨ¹ý¼à²â¿¹FXaµÄˮƽÁìµ¼ÓÃÒ©¼ÁÁ¿¡¾1B¡¿ ¡£

  • ÀûÓÃLMWHÒ½Öμ±ÐÔDVTʱ£¬Èô¹é²¢ÑϳÁÉöÖ°Äܲ»È«£¨¼¡ôû¶Ï¸ùÂÊ<30 ml/minʱ£¬É÷ÓÃLMWH£©£¬½¨ÒéLMWH¼õÁ¿²¢¼à²â¿¹FXa»îÐÔ¡¾2C¡¿ ¡£


¡¶¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÒ½ÖÎÖйúר¼Ò¹²Ê¶£¨2015£©¡·¶ÔµÍ·Ö×Ó¸ÎËØµÄÒ½ÖÎÁìÓòÒ²¸ø³öÁ˽¨Ò飺»³Ì¥ÆÚ¼äÐ趨ÆÚ¼à²â¿¹Xa»îÐÔ£¬Æä·åÖµÓ¦ÔÚ×î½üÒ»´Î×¢Éäºó4h²â¶¨£¬¹ÈÖµÓ¦±ÉÈË´Î×¢Éäǰ²â¶¨£¬¿¹Xa»îÐÔÖ¸±êÁìÓòΪ0.6¡«1.0 IU£¯ml£¬Ã¿Ìì¸øÒ©1´ÎµÄÖ¸±êÁìÓòΪ1.0¡«2.0 IU£¯ml ¡£


ºÜ¶à»ú¹¹Ê¹Óÿ¹XaÒò×Ó»îÐԲⶨ×÷Ϊ½ð³ß¶È²âÊÔ£¬ÒÔ¼à²âºÍµ÷ÕûÒ½ÖÎÐÔδ·Ö×é¸ÎËØºÍµÍ·Ö×Ó¸ÎËØÒ½ÖεÄÖÎÀí ¡£

¡ª¡ª¡¶ELSO Anticoagulation Guideline¡·


ÏÔÉ«¿¹XaÒò×ӲⶨÊÇĿǰ¼à²âµÍ·Ö×Ó¸ÎËØÒ½ÖεĽð³ß¶È ¡£

¡ª¡ª¡¶Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux¡·


ʹÓÃUFHºÍLMWH½øÐп¹ÄýÒ½ÖÎʱ£¬ÏÂÁÐÈËȺ±ØÒª½øÐмà²â£º


  • Ó¤Ó×¶ùºÍ¶ùͯ

  • ÀÏÈË£¨´ºÇ85Ë꣩

  • Ìå³ÁÒì³£Õß

  • ¼¡ôû¶Ï¸ùÂÊÔÚ15¡«30 mL£¯minµÄÂýÐÔÉö²¡Õß

  • »³Ì¥¸¾Å®

  • ÓгöѪ·çÏյϼÕßµÈ


¿¹Xa»îÐÔ¼ì²â


¼ì²âµÀÀíΪ£ºÑù±¾ÖеĸÎËØÓ뿹ÄýѪø½áºÏÐγɸ´ºÏÎïºó£¬»áÓ벿ÃÅXa½áºÏ£¬²¢Ê¹ÕⲿÃÅXaʧ»î ¡£Ôü×ÒµÄXa¿É½«ºÏ³ÉµÄÏÔÉ«µ×Îï·Ö»¯²úÉú¶ÔÏõ»ù±½°·£¨PNA£©£¬PNAÔÚ405nm´¦ÓÐ×î´óÎüÊշ壬ͨ¹ý²â¶¨¶ÔÏõ»ù±½°·µÄÐγÉÁ¿À´ÍÆËã¸ÎËØ»îÐÔ ¡£


1

¿¹Xa»îÐÔ¼ì²âµÀÀíͼ


ÊÔ¼Á»úÄÜ


k¶¹Ç®°ü¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©Í¨¹ýÉ«²Ê±ä¶¯À´²â¶¨¿¹ÄýÇ¿¶È/ѪҩŨ¶È£¬ÏßÐÔ¿í£¬¿¹×ÌÈÅÄÜÁ¦Ç¿£¬¾«Ãܶȸߣ¬ÓëÊг¡Ö÷Á÷³§¼ÒÊÔ¼ÁÓйØÐÔÓÅÁ¼£¬R2£¾0.95£¬¿ÉÂú×ãÁÙ´²¼ì²âÐèÒª ¡£


2

£¨Êý¾ÝÆðÔ´£º¿¹Xa¶àÖÐÐÄÒ½ÔºÑù±¾±È¶ÔÊý¾Ý£©


½ð˹¶û¿¹XaÊÔ¼ÁÄܹ»Âú×ãÁÙ´²Ô¤ÆÚÓô¦£º

½ð˹¶û¿¹XaÊÔ¼ÁºÐͨ³£¸ÎËØÏßÖ°Äܹ»×öµ½4IU/mL£¬²»½öÄܹ»Âú×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL£¬Í¬Ê±Äܹ»Âú×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÒª ¡£

3

¿¹×ÌÈÅÄÜÁ¦Ç¿£º

k¶¹Ç®°ü¿¹XaÊÔ¼ÁºÐ²¿ÃÅÖ¸±ê£¬¿¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á ¡£

4


Ó×½á

¿¹Xa»îÐÔÊÔÑé¿ÉÓÃÓÚUFH¡¢LMWHµÈ¶àÖÖÒ©ÎÄýÇ¿¶È/ѪҩŨ¶ÈµÄ²â¶¨ ¡£


4¼ÒÈý¼×Ò½Ôº¹²Í¬²Î¼ÓÁËÖйú×êÑÐÐÍҽԺѧ»áµÄ¡°¹ú²ú¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©¶àÖÐÐÄÏîÄ¿»úÄÜÆÀ¼Û¡±£¨ÏîÄ¿±àºÅ£ºY2021FH-XSYZX04£©¿ÎÌ⣬¾­¶àÖÐÐij¢ÊÔÁ˾ÖÂÛÖ¤£º

£¨1£©¹ú²ú¿¹XaºÍ¶ÔÕÕÊÔ¼ÁµÄ²âÖµµÄÓйØÐÔÓÅÁ¼£ºÎÞÂÛÊÇͨ³£¸ÎËØ»¹ÊǵͷÖ×Ó¸ÎËØ£¬²âÖµÓйØÐÔ¾ùÔÚR2£¾0.95£¬¿ÉÂú×ãÁÙ´²¼ì²âÐèÒª£»

£¨2£©¹ú²ú¿¹XaÊÔ¼ÁÄܹ»Âú×ãÁÙ´²Ô¤ÆÚÓô¦£ºk¶¹Ç®°ü¿¹XaÊÔ¼ÁºÐͨ³£¸ÎËØÏßÖ°Äܹ»×öµ½4IU/mL£¬²»½öÄܹ»Âú×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL£¬Í¬Ê±Äܹ»Âú×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÒª£»

£¨3£©¹ú²ú¿¹XaÊÔ¼Á»úÄÜÆÀ¼ÛÓÅÁ¼£¬ÎªÁÙ´²Ìṩ¹ú²ú´úÌæµÄÑ¡Ôñ£º»úÄÜÆÀ¼ÛÊý¾ÝÏÔʾ£¬k¶¹Ç®°ü¿¹XaÊÔ¼ÁºÐµÄ¸÷Ïî»úÄÜÓÈÆäÊÇÔÚ¿¹×ÌÈÅÄÜÁ¦·½Ã棬¶ÔÖ±½Óµ¨ºìËØºÍѪºìµ°°×µÄ¿¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á ¡£


5




¡¶¿¹Xa¶àÖÐÐÄÁ˾ֻ㱨Óë·ÖÎö¡·

ÅÔ¹Ûͨ·

¢Ù PC¶ËÊäÈëÏ·½Á´½Ó¼´¿ÉµÇ¼ÄýÑªÔÆ½²ÌÃÆ½Ì¨£¬ÅÔ¹ÛÊÓÆµ£º

https://vfs.xet.tech/s/2YYnDS

¢Ú H5¶Ë¼ø±ðÏ·½¶þάÂ룬¼´¿ÉÌø×ªÖÁÊÓÆµÒ³Ã棺

6



k¶¹Ç®°üѪÄý¼ì²âϵͳ


k¶¹Ç®°üÉúÎïÊÇÖйúµ±ÏȵÄÁÙ´²Ìå±íÕï¶Ï²úÆ·Óë·þÎñ¹©¸øÉÌÖ®Ò»£¬Ä¿Ç°Õ¼ÓÐ×ÔÖ÷Ñз¢µÄÈ«×Ô¶¯ÄýѪ¼ì²â·ÖÎöÒÇMDC7500ºÍMDC3500ÒÔ¼°µÂ¹úÔ­×°½ø¿ÚµÄCoatron5000¡¢Coatron3000ºÍCoatron1800£¬×¨ÒµÅäÌ×µÄÄýѪ¼ì²âÊÔ¼ÁÔÚÂú×ã×ÔÓмì²âϵͳµÄͬʱҲÄÜÃÀÂúÆ¥ÅäÖ÷Á÷ѪÄý¼ì²âϵͳ£¬Âú×ã·ÖÆç¿Í»§µÄÐèÒª£¬ÎªÁÙ´²Ìá¹©È«ÃæµÄѪ˨ÓëֹѪ³¢ÊÔÊÒ½â¾ö¹æ»® ¡£


7


8



²Î¿¼Îļþ

[1] ÖлªÒ½Ñ§»áÐÄѪ¹Ü²¡Ñ§·Ö»á·ÎѪ¹Ü²¡Ñ§×é.¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÒ½ÖÎÖйúר¼Ò¹²Ê¶(2015)[J].ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾,2016,44(3):197-211.

[2] ÀµÓîÒ¢,Àî¹ðɺ,ÍõÖ¾Ã÷,µÈ.¿¹Xa»îÐÔ¼ì²âÔÚ¿¹ÄýÒ©Îï¼à²âÖеÄÀûÓÃ[J].ÏóÕ÷ÃâÒß·ÖÎöÓëÁÙ´²,2020,27(8):1444-1449.

[3] Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl): e737S-e801S.

[4] ÕźèÑÞ,Èξ²,ÃŽ£Áú.¿¹ÄýÒ©ÎïµÄ³¢ÊÔÊÒ¼à²â[J].ÖйúÐÄѪ¹ÜÔÓÖ¾,2019,24(6):565-570.

[5] Vandiver J W , Vondracek T G . Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin[J]. Pharmacotherapy, 2012, 32(6):546-558.

[6] The Extracorporeal Life Support Organization (ELSO).ELSO Anticoagulation Guideline.2014, 1-17.

[7] Babin JL, Traylor KL, Witt DM. Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. Semin Thromb Hemost. 2017 Apr;43(3):261-269.

[8] ëøæÂ,ÀîÓÂÄÐ,Â¥ËÉ.¿¹Xa»îÐÔÔÚͨ³£¸ÎËØ¿¹Äý¼à²âÖÐÀûÓõÄ×êÑнøÕ¹[J].ÖйúÌå±íÑ­»·ÔÓÖ¾,2018,16(4):248-251.

[9] Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265-72. 

¸ßµÍ»¬¶¯²é¿´ÆëÈ«²Î¿¼Îļþ



END

ÎÄÕÂÆðÔ´£ºk¶¹Ç®°üÉúÎï

Ôð±à£ºEcho

У¶Ô£ºÓ׾š¢Cassie


 
¡¾ÍøÕ¾µØÍ¼¡¿